Objectives: To determine the effect of physiologic catecholamine concentrations on the defibrillation threshold (DFT) in patients with implanted cardioverter defibrillators. Background: DFT is the ...

Defibrillation testing during implantation of cardioverter–defibrillators is controversial because of potential safety concerns and a lack of evidence for the effectiveness of the procedure. New data ...

BOSTON — An investigative small-diameter defibrillation lead for implantable cardioverter-defibrillators has exceeded its safety and efficacy expectations in a pivotal clinical trial. The LEADR trial ...

The OmniaSecure lead was placed in the desired right ventricular location in 99.5% of patients and achieved successful defibrillation testing at implantation in 97.5%. Freedom from study lead-related ...